🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07330453
Starting soon Observational

Cardiovascular Surgery Early Prediction System for AKI :CARDS-AKI Registry

NCT07330453 · tracked via the Priya Life Science China tracker
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Phase
Observational
Started
2025-12-25
Last updated
2026-01-09

Condition(s) studied

Cardiovascular Surgery

Investigational drug(s) / intervention(s)

Observation

Observation: As an observational study, patients' therapeutic approach will not be modified during the course of this research.

Study summary

This multicenter, prospective study prospectively enrolled patients undergoing cardiovascular surgery. Detailed perioperative clinical data and biospecimens were collected at multiple time points. The primary aim is to develop an early warning model for postoperative acute kidney injury (AKI) by integrating clinical data and biomarkers. Additionally, through long-term follow-up, the study seeks to characterize outcome trajectories and establish a prognostic model for AKI patients.

This study addresses four key questions: 1) Integration of clinical information and biomarkers to develop an early predictive model for cardiac surgery-associated acute kidney injury (CSA-AKI); 2) Identification of risk factors for CSA-AKI occurrence; 3) Determinants of prognosis in patients with CSA-AKI; and 4) Enhanced prediction of near- and long-term clinical event risks in this patient population.

Participants will receive standard perioperative management. The study protocol includes the following procedures:(1) Clinical Data Collection: Comprehensive perioperative clinical data will be systematically recorded. (2) Biospecimen Sampling: Serial blood and urine samples will be obtained at predefined time points throughout the perioperative period. (3) In-Hospital Monitoring: Clinical outcomes will be continuously monitored during the hospital stay. (3) Post-discharge Follow-up: Participants will be assessed at regular intervals after discharge to track the occurrence of major adverse events.

These findings provide a foundational basis for the development of a data-driven early-warning system. Such a system is designed to facilitate the prompt identification of high-risk patients and enable the initiation of personalized treatment strategies, thereby potentially improving clinical outcomes and optimizing resource allocation

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: * Age ≥ 18 years; * Scheduled to undergo elective cardiac surgery; * Able to complete baseline data collection and provide written informed consent. Exclusion Criteria: * Preoperative serum creatinine \> 353 μmol/L, history of or currently receiving dialysis therapy. * History of kidney transplantation. * Presence of malignant tumors.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fuwai Hospital, Chinese Academy of Medical Science Beijing Beijing Municipality

More Chinese Academy of Medical Sciences, Fuwai Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07330453 on ClinicalTrials.gov ↗ ← All trials in China